Abstract
Full Text Available
Keywords: DHA supplementation, cognitive decline, Alzheimers disease, herbal supplements
Current Alzheimer Research
Title: Memory Improvement with Docosahexaenoic Acid Study (MIDAS)-Brief Review
Volume: 4 Issue: 5
Author(s): Karin Yurko-Mauro
Affiliation:
Keywords: DHA supplementation, cognitive decline, Alzheimers disease, herbal supplements
Abstract: Full Text Available
Export Options
About this article
Cite this article as:
Yurko-Mauro Karin, Memory Improvement with Docosahexaenoic Acid Study (MIDAS)-Brief Review, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018244
DOI https://dx.doi.org/10.2174/156720507783018244 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Past and Future Perspectives of Synthetic Peptide Libraries
Current Protein & Peptide Science Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
CNS & Neurological Disorders - Drug Targets ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer's Disease
Current Computer-Aided Drug Design MicroRNAs: Macro Challenges on Understanding Human Biological Functions and Neurological Diseases
Current Molecular Medicine In Vitro and In Vivo Metabolism of a Gamma-Secretase Inhibitor BMS-299897 and Generation of Active Metabolites in Milligram Quantities with a Microbial Bioreactor
Current Drug Metabolism Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Current Pharmaceutical Biotechnology Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Paediatric Antiretroviral Drug Targets
Infectious Disorders - Drug Targets Does an Interdisciplinary Network Improve Dementia Care? Results from the IDemUck-Study
Current Alzheimer Research Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia: Probing for Markers
CNS & Neurological Disorders - Drug Targets New Proposals for Treatment Sporadic Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Prolyl Oligopeptidase in Brain Function and Dysfunction (Guest Editor: J. Arturo Garcia-Horsman)]
CNS & Neurological Disorders - Drug Targets Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Design and Synthesis of New Dual Binding Site Cholinesterase Inhibitors: in vitro Inhibition Studies with in silico Docking
Letters in Drug Design & Discovery Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Conference Report: 9th Clinical Trials on Alzheimer's Disease (CTAD): Marriott Marquis San Diego Marina, San Diego, CA, USA December 8-10, 2016
CNS & Neurological Disorders - Drug Targets